Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Study of Transdermal Testosterone Patches in Surgically Menopausal Women With Low Libido
This study has been completed.
Sponsored by: Procter and Gamble
Information provided by: Procter and Gamble
ClinicalTrials.gov Identifier: NCT00331214
  Purpose

This study is designed to evaluate efficacy and safety of a testosterone patch as treatment for low libido in surgically menopausal women who are taking estrogen therapy.


Condition Intervention Phase
Hypoactive Sexual Desire Disorder
Drug: Testosterone Transdermal System
Drug: placebo patch
Phase III

MedlinePlus related topics: Menopause
Drug Information available for: Testosterone Methyltestosterone Oxymesterone Testosterone enanthate Testosterone Propionate Testosterone undecanoate
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Safety Study
Official Title: Study to Evaluate the Efficacy and Safety of Transdermal Testosterone in Women With Hypoactive Sexual Desire Disorder on Concurrent Estrogen Replacement Therapy and Undergone Hysterectomy/Bilateral Oophorectomy

Further study details as provided by Procter and Gamble:

Primary Outcome Measures:
  • To assess the efficacy of testosterone transdermal system (TS) as measured by the change from baseline in the frequency of total satisfying sexual activity captured by the Sexual Activity Log (SAL). [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To assess the efficacy measured by the change from baseline in sexual desire; personal distress as measured by the Personal Distress Scale score; the other 6 domains of the profile of Female Sexual Function; and the other 8 SAL endpoints. [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Enrollment: 533
Study Start Date: June 2002
Study Completion Date: July 2006
Primary Completion Date: December 2003 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1: Sham Comparator
placebo patch fro 6 months
Drug: placebo patch
placebo patch replaced every 3-4 days for 6 months
2: Experimental
Testosterone patch
Drug: Testosterone Transdermal System
testosterone patch (300mcg/day), patch changed twice a week fro six months

Detailed Description:

Women with hypoactive sexual desire disorder (HSDD) who had undergone bilateral salpingo-oophorectomy and hysterectomy were randomized into a 24-week, multicenter, multinational, double-blind (DB), parallel-group, placebo-controlled study. Patients were stratified based on their use of oral or transdermal ET and randomized to receive placebo or testosterone transdermal system. Patients had to maintain a stable dose of estrogen throughout the study. Patients who completed the first 24 weeks of the study were given the opportunity to participate in a 3.5 year open-label (active treatment) study extension which was added to the protocol by amendment. Safety was assessed by adverse events, lipids, serum chemistry with hepatic, renal and carbohydrate metabolism evaluation, and hematology. Physical exam including clinical assessments of facial hair and acne were monitored.

  Eligibility

Ages Eligible for Study:   20 Years to 70 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Eligible women must:

  1. Be 20-70 years old and in generally good health
  2. Have undergone hysterectomy and removal of both ovaries at least 6 months prior to screening
  3. Be receiving a stable dose of estrogen replacement therapy for at least 3 months prior to screening with the intention of maintaining that regimen.
  4. Be, in her own judgment, in a stable monogamous sexual relationship that is perceived to be secure and communicative, for at least one year prior to study entry.
  5. Meet the criteria for having hypoactive sexual desire disorder.

Exclusion Criteria:

Eligible women must not:

  1. Have received androgen therapy at any time during the past 3 months (during the past 7 months if therapy was an investigational implantable product)
  2. Be experiencing any chronic or acute life stress relating to any major life change
  3. Be experiencing depression and/or receiving medication for such illness or disorder
  4. Have current severe skin problems (such as severe or cystic acne) or allergy to adhesives (like the ones in bandages)
  5. Have had a major illness, active gall bladder disease, or gynecological or breast surgery within the last 6 months
  6. Have a history of breast, endometrial, or other gynecological cancer at any time before study participation or other cancer within the last 5 years
  7. Have diabetes, a history of cerebrovascular disease, thromboembolic disorders, heart attack, or angina at any time before study participation or thrombophlebitis within the last 5 years
  8. Have abnormal laboratory test results upon initial screening for this study
  9. Have previously participated in P&GP study 1999068 or 1999092
  10. Have previously participated in a clinical trial within 30 days or received an investigation medication within 30 days.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00331214

Locations
United States, Colorado
Research Site
Denver, Colorado, United States
Australia, Queensland
Research Site
Nedlands, Queensland, Australia
Canada, Ontario
Research Site
Kingston, Ontario, Canada
Sponsors and Collaborators
Procter and Gamble
Investigators
Study Director: Johna Lucas, MD Procter and Gamble
  More Information

Responsible Party: Procter and Gamble Pharmaceuticals ( Johna Lucas, MD )
Study ID Numbers: 2001134 and Yr 2-4 OL
Study First Received: May 26, 2006
Last Updated: February 6, 2008
ClinicalTrials.gov Identifier: NCT00331214  
Health Authority: United States: Food and Drug Administration;   Canada: Health Canada;   Australia: Department of Health and Ageing Therapeutic Goods Administration

Keywords provided by Procter and Gamble:
Surgical menopause
HSDD

Study placed in the following topic categories:
Sexual Dysfunctions, Psychological
Signs and Symptoms
Testosterone
Mental Disorders
Neurologic Manifestations
Methyltestosterone
Hypokinesia
Dyskinesias
Menopause
Testosterone 17 beta-cypionate

Additional relevant MeSH terms:
Disease
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Nervous System Diseases
Physiological Effects of Drugs
Hormones, Hormone Substitutes, and Hormone Antagonists
Sexual and Gender Disorders
Hormones
Pharmacologic Actions
Anabolic Agents
Pathologic Processes
Therapeutic Uses
Androgens

ClinicalTrials.gov processed this record on January 15, 2009